In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …

Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at
present. To address this challenge, we need a paradigm shift, where we focus on pre …

Introduction We aim to study the effect of a more precise diagnosis, by means of amyloid
positron emission tomography (PET), on institutionalization, mortality, and health‐care costs …

Growing evidence suggests dementia incidence can be reduced through prevention
programs targeting risk factors. To accelerate the implementation of such prevention …

Background The paradigm shift towards earlier Alzheimer's disease (AD) stages and
personalized medicine creates new challenges for clinician-patient communication. We …

Background and purpose Careful counseling through the diagnostic process and adequate
postdiagnostic support in patients with mild cognitive impairment (MCI) is important …

Background Mild cognitive impairment (MCI) is a condition that exists between normal
healthy ageing and dementia with an uncertain aetiology and prognosis. This uncertainty …

Background: Literature supports the use of serious games and virtual environments to
assess cognitive functions and detect cognitive decline. This promising assessment method …

INTRODUCTION We described patients' and care partners' experiences with Alzheimer's
disease (AD) cerebrospinal fluid (CSF) biomarker testing and result disclosure in routine …